Recombinant Human MMP8/CLG1 protein (His Tag)

Catalog Number: PDMH100408

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description	
Species	Human
Source	HEK293 Cells-derived Human MMP8 protein Met1-Gly467, with an C-terminal His
Calculated MW	51.3 kDa
Observed MW	75 kDa
Accession	P22894
Bio-activity	Not validated for activity
Properties	
Purity	>95% as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU/mg of the protein as determined by the LAL method
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of
	reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%
	Mannitol.
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of
	0.5 mg/mL. Concentration is measured by UV-Vis.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that degrade components of the extracellular matrix (ECM) and play essential roles in various physiological processes such as morphogenesis, differentiation, angiogenesis and tissue remodeling, as well as pathological processes including inflammation, arthritis, cardiovascular diseases, pulmonary diseases and tumor invasion. Neutrophil collagenase, also known as Matrix metalloproteinase-8, MMP-8, and CLG1, is a member of the peptidase M10A family. MMP-8 may affect the metastatic behaviour of breast cancer cells through protection against lymph node metastasis, underlining the importance of anti-target identification in drug development. MMP-8 in the tumour may have a protective effect against lymph node metastasis. MMP-8 may affect the metastatic behaviour of breast cancer cells through protection of breast cancer cells through protection in drug development. MMP-8 in the tumour may have a protective against lymph node metastasis, underlining the importance of anti-target identification in drug development of breast cancer cells through protection against lymph node metastasis, underlining the importance of anti-target identification in drug development. MMP-8 is the tumour may have a protective against lymph node metastasis, underlining the importance of anti-target identification in drug development. MMP-8 participates in wound repair by contributing to the resolution of inflammation and open the possibility to develop new strategies for treating wound healing defects.